上半年，公募这样“擒牛”

Core Viewpoint - The article discusses the performance of A-shares and Hong Kong stocks in the first half of the year, highlighting the emergence of numerous "bull stocks" and the strong performance of funds focused on specific sectors, particularly in innovative pharmaceuticals and new consumption [1]. Group 1: Market Performance - As of June 30, 2023, 136 A-share companies saw their stock prices increase by over 100%, with notable stocks in the Hong Kong market, such as Old Puhuang and Rongchang Biopharmaceutical, experiencing gains close to 200% [1]. - The average return of actively managed equity funds was 7.32%, with a median return of 5.33%, outperforming the three major A-share indices [1]. Group 2: Fund Holdings - The top-performing fund, Huatai PineBridge Hong Kong Advantage Selected Mixed Fund, has significant holdings in Rongchang Biopharmaceutical and other leading Hong Kong pharmaceutical stocks [3]. - As of the first quarter of 2025, 57 fund companies held a total of 6,874,750 shares of Pop Mart, with a 31-fund increase in heavy holdings compared to the previous quarter [3]. - Public funds collectively held 550,150 shares of Old Puhuang, valued at 3.657 billion yuan, with significant contributions from the Guangfa Growth Leading Fund [3]. Group 3: Investment Strategies - Accurate assessment of fundamentals is crucial for identifying potential bull stocks, especially in the innovative pharmaceutical sector, where companies may not show immediate profits during their capability-building phase [4]. - The focus for the second half of the year will be on sectors like AI and innovative pharmaceuticals, with expectations for significant opportunities in AI hardware and software due to technological advancements [4]. Group 4: Industry Outlook - The innovative pharmaceutical sector is experiencing a dual-driven market of valuation recovery and fundamental improvement, with the A-share Shenwan Biomedicine Index's dynamic P/E ratio at a low point historically [5]. - The Chinese innovative pharmaceutical industry is entering a results realization phase, with some companies showing strong potential compared to global peers, warranting close monitoring of their R&D progress and overseas licensing dynamics [5].